Here, we show that a more specific SETD8 inhibitor with enhanced activity and selectivity, SGSS05-NS3 rescues the canonical p53 functions, restores p53-mediated DNA damage response, and in pre-clinical xenograft NB models confers a significant survival advantage in MYCN-WT NB. This evidence concerns the gene KRAS and neuroblastoma.